Adfinitas Health

AdfinitasHealth.com

Adfinitas Health (formerly MDICS) is the trusted partner of more than 50 healthcare systems, hospitals, and post-acute care centers in the Mid-Atlantic region. Founded in 2007, this physician-owned and managed company provides high-quality, cost-effective integrated medical services across the full continuum of care in hospitals and post-acute facilities. Its unique integrated staffing model, unwavering commitment to client satisfaction, and focus on improving patient outcomes, make possible real opportunities to transform care and drive value for its clients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

MELINTA THERAPEUTICS PARTNERS WITH BARDA TO ADVANCE TWO FDA-APPROVED ANTIBIOTICS FOR USE IN PEDIATRIC PATIENTS

Businesswire | July 11, 2023

news image

Melinta Therapeutics, LLC a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to advance two antibiotics currently FDA-approved for adults, BAXDELA® (delafloxacin) and VABOMERE® (meropenem and vaborbactam), for use in pediatrics. In addition, Melinta and BARDA will partner on the development of BAXDELA® against biothreat pathogens...

Read More

Industrial Impact

AGILENT AND A*STAR’S SIFBI SIGN RESEARCH COLLABORATION AGREEMENT TO ADVANCE SINGAPORE AGRI-FOOD INDUSTRY

Agilent Technologies Inc. | January 27, 2022

news image

Agilent Technologies Inc. recently signed a Research Collaboration Agreement with the Singapore Institute of Food and Biotechnology Innovation outlining their collaboration on developing food research knowledge advancement over the next two years. SIFBI is a research institute under the Agency for Science, Technology, and Research in Singapore. This collaboration aims to bring state-of-the-art science and technology to drive innovation in food, nutrition, ingredients, industrial b...

Read More

Medical

BIOCYTOGEN ENTERS INTO BISPECIFIC ANTIBODY DRUG CONJUGATE AGREEMENT WITH RADIANCE BIOPHARMA

Biocytogen | January 15, 2024

news image

Biocytogen Pharmaceuticals Co., Ltd. a global biotech company focusing on the discovery of novel antibody therapeutics, announces that it has entered into an Exclusive Option and License Agreement with Radiance Biopharma Inc. a biotechnology company specializing in developing next generation Antibody Drug Conjugates. The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate (BsADC) for thera...

Read More

Industrial Impact

IFF TO ACQUIRE HEALTH WRIGHT PRODUCTS

IFF | February 17, 2022

news image

IFF announced that it has entered into an agreement to acquire Health Wright Products, LLC (HWP), a leader in formulation and capsule manufacturing for the dietary supplement industry. Founded in 1995, HWP is located in Clackamas, Oregon, USA, and is a privately-owned and long-time business partner of IFF’s Health & Biosciences probiotics business. HWP is a global leader in the consumer Health and Nutrition industries, providing the highest-quality nutritional supplement...

Read More
news image

Medical

MELINTA THERAPEUTICS PARTNERS WITH BARDA TO ADVANCE TWO FDA-APPROVED ANTIBIOTICS FOR USE IN PEDIATRIC PATIENTS

Businesswire | July 11, 2023

Melinta Therapeutics, LLC a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to advance two antibiotics currently FDA-approved for adults, BAXDELA® (delafloxacin) and VABOMERE® (meropenem and vaborbactam), for use in pediatrics. In addition, Melinta and BARDA will partner on the development of BAXDELA® against biothreat pathogens...

Read More
news image

Industrial Impact

AGILENT AND A*STAR’S SIFBI SIGN RESEARCH COLLABORATION AGREEMENT TO ADVANCE SINGAPORE AGRI-FOOD INDUSTRY

Agilent Technologies Inc. | January 27, 2022

Agilent Technologies Inc. recently signed a Research Collaboration Agreement with the Singapore Institute of Food and Biotechnology Innovation outlining their collaboration on developing food research knowledge advancement over the next two years. SIFBI is a research institute under the Agency for Science, Technology, and Research in Singapore. This collaboration aims to bring state-of-the-art science and technology to drive innovation in food, nutrition, ingredients, industrial b...

Read More
news image

Medical

BIOCYTOGEN ENTERS INTO BISPECIFIC ANTIBODY DRUG CONJUGATE AGREEMENT WITH RADIANCE BIOPHARMA

Biocytogen | January 15, 2024

Biocytogen Pharmaceuticals Co., Ltd. a global biotech company focusing on the discovery of novel antibody therapeutics, announces that it has entered into an Exclusive Option and License Agreement with Radiance Biopharma Inc. a biotechnology company specializing in developing next generation Antibody Drug Conjugates. The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate (BsADC) for thera...

Read More
news image

Industrial Impact

IFF TO ACQUIRE HEALTH WRIGHT PRODUCTS

IFF | February 17, 2022

IFF announced that it has entered into an agreement to acquire Health Wright Products, LLC (HWP), a leader in formulation and capsule manufacturing for the dietary supplement industry. Founded in 1995, HWP is located in Clackamas, Oregon, USA, and is a privately-owned and long-time business partner of IFF’s Health & Biosciences probiotics business. HWP is a global leader in the consumer Health and Nutrition industries, providing the highest-quality nutritional supplement...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us